To the Editor: Sweeney et al. (Aug. 20 issue)(1) report a marked survival advantage with concomitant docetaxel and androgen-deprivation therapy (ADT), as compared with ADT alone, in patients with hormone-sensitive metastatic prostate cancer.
However, it would be interesting to compare the experimental group with the subgroup of the control group that received subsequent docetaxel after the development of castration resistance to clarify the effect of timing on patient outcomes. In addition, the survival benefit was more pronounced in high-risk patients, with an extraordinary hazard ratio of 0. 61. This underlines the need for more accurate models integrating data on disease volume . . .
The New England journal of medicine. 2016 Jan 21 [Epub]
Chiara Ciccarese, Matteo Santoni, Francesco Massari